ClinicalTrials.gg
CompletedNCT01020396Updated Aug 19, 2024

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

A Phase 1/2 interventional study of Metronidazole and Metronidazole in Bacterial Vaginosis, sponsored by Teva Pharmaceuticals USA. Completed at 37 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1/2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
579
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing metronidazole in Vaginosis, Bacterial — 2 open to participants now, 2 under way, 1 of them phase 3. Metronidazole · Vaginosis, Bacterial.

Enrollment
7th of 21
579 · median 166
Started
2002
with 1 other
Phase 1/2
Only one
of the 21
Registered
6th of 21
by date

Among the 21 studies testing metronidazole in Vaginosis, Bacterial, this one is the 7th largest by enrollment, is one of 2 that started in 2002, is the only one in phase 1/2, and was the 6th registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

2 of the 21 studies testing metronidazole in Vaginosis, Bacterial are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About metronidazole

Metronidazole: first FDA approval 1963 (FLAGYL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing metronidazole in Vaginosis, Bacterial, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal® metronidazole vaginal gel, 0.75% to establish clinical equivalence in the treatment of bacterial vaginosis.

03

Conditions studied

  • Bacterial Vaginosis

Keywords

  • Bioequivalence
  • Metronidazole
  • Vaginosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must provide written prior to any study related procedures being performed.
  • Female subjects must have a clinical diagnosis of bacterial vaginosis, defined as having the presence of "clue cells" > 20% of the total epithelia cells on microscopic examination of a saline "wet mount" and all of the following criteria: Off-white (milky or grey), thin, homogeneous discharge; pH of vaginal fluid > 4.7; a positive 10% KOH "whiff test".
  • Subjects must be 18 years of age or older with no known medical conditions that, in the investigator's opinion, may interfere with study participation.
  • Women of child bearing potential must have a negative urine pregnancy test result upon entry into the study.
  • Subjects must agree to abstain from sexual intercourse throughout the first 7 days of the study. Following the first 7 days, subjects must agree to use a non-lubricated condom when engaging in sexual intercourse.
  • Subjects must be willing to abstain from alcohol ingestion during the 5 day treatment period and for 1 day afterward.
  • Subjects must agree to refrain from the use of intra-vaginal products throughout the study (e.g., douches, feminine deodorant sprays, spermicides, lubricated condoms, tampons, and diaphragms).

Exclusion criteria

Exclusion Criteria:

  • Subjects with known or suspected other infectious causes of vulvovaginitis (e.g. candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, active Herpes simplex or human papilloma virus, or any other vaginal or vulvar condition, which in the investigator's opinion, would confound the interpretation of the clinical response).
  • Subjects with a Gram's stain slide Nugent score \<4.
  • Subjects who received antifungal or antimicrobial therapy (systemic or intravaginal) within 14 days of randomization.
  • Subjects who have taken disulfuram within 14 days or randomization.
  • Subjects who have demonstrated a previous reaction to metronidazole, either orally or topically administered, or any form or parabens.
  • Subjects with primary or secondary immunodeficiency.
  • Women who will be under treatment during the study period for cervical intra-epithelial neoplasia (CIN) or cervical carcinoma.
  • Subjects who are pregnant, breast feeding, or planning a pregnancy.
  • Subjects who are menstruating at the time of diagnosis.
  • Subjects with intrauterine devices.
  • Concurrent anticoagulation therapy with coumadin or warfarin.
  • Concurrent use of systemic or systemic antibiotics.
  • Subjects with unstable medical disorders, life threatening diseases or current .
  • Subjects previously enrolled in this study.
  • Subjects who have participated in another clinical trial or have taken an experimental drug within the past 30 days.
  • Subjects who are unwilling or unable to comply with the requirements of the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
579 participants (actual)

Study arms

  • Experimental
    1

    Metronidazole Vaginal Gel, 0.75% (Teva Pharmaceuticals, USA)

    Drug: Metronidazole

  • Active comparator
    2

    MetroGel-Vaginal® metronidazole vaginal gel, 0.75% (3M Pharmaceuticals)

    Drug: Metronidazole

Interventions

06

What researchers measure

Primary outcomes

  1. Therapeutic cure rate of the subject at the Test-of-Cure Visit.

    Time frame: Visit 3

  2. Incidence of Adverse Effects reported throughout the study.

    Time frame: 29 Days

Secondary outcomes

  1. Therapeutic cure rate at the Post-Treatment Visit

    Time frame: Visit 2

07

Study locations

37 sites
  • Clinic for Women, PA
    Huntsville, Alabama 35801, United States
  • Medical Affiliated Research Center, Inc.
    Huntsville, Alabama 35801, United States
  • Edinger Medical Group
    Fountain Valley, California 92708, United States
  • Office of Drs. Shepard and Lugerner, PC
    Washington, District of Columbia 20006, United States
  • Meadowcrest Women's Center
    Crystal River, Florida 34429, United States
  • Florida Medical and Research Institute, PA
    Gainesville, Florida 32607, United States
  • The Florida Wellcare Alliance, LC
    Inverness, Florida 34452, United States
  • Wellness Center for Gyn & Osteoporosis
    Inverness, Florida 34452, United States
  • Florida Medical and Research Institute, PA
    Ocala, Florida 34471, United States
  • KGR, LLC
    Riverdale, Georgia 30274, United States
  • Women's Health Practice
    Champaign, Illinois 61820, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • New Orleans Institute of Clinical Investigation
    New Orleans, Louisiana 70112, United States
  • Phoenix Ob-Gyn Associated
    Moorestown, New Jersey 08057, United States
  • Phoenix Ob-Gyn Associates
    Mount Holly, New Jersey 08060, United States
  • Kings County Hospital Center
    Brooklyn, New York 11203, United States
  • SUNY Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Chapel Hill Obstetrics and Gynecology, PA
    Chapel Hill, North Carolina 27514, United States
  • Cooperfield Obstetrics and Gynecology, LLC
    Concord, North Carolina 28025, United States
  • O.U. Physicians' Building
    Oklahoma City, Oklahoma 73104, United States
  • The OU Medical Center
    Oklahoma City, Oklahoma 73104, United States
  • University of Oklahoma Health Services Center
    Oklahoma City, Oklahoma 73104, United States
  • Medford Women's Clinic
    Medford, Oregon 97504, United States
  • Philadelphia Women's Research
    Philadelphia, Pennsylvania 19114, United States
  • Elite Medical Research, Inc.
    Sellersville, Pennsylvania 18960, United States
  • Stonebridge OB/GYN Associates
    Sellersville, Pennsylvania 18960, United States
  • Anderson Family Care
    Anderson, South Carolina 29621, United States
  • Carolina OB/GYN
    Anderson, South Carolina 29621, United States
  • Primary Care Associates
    Anderson, South Carolina 29621, United States
  • Radiant Research
    Anderson, South Carolina 29621, United States
  • Research Memphis
    Memphis, Tennessee 38116, United States
  • Millennium Clinical Research Center, LLC
    Arlington, Virginia 22203, United States
  • Women's Health Associates, PC
    Fairfax, Virginia 22031, United States
  • Office of H. Sharon Sethi
    Fairfax, Virginia 22033, United States
  • MedSource, Inc.
    Richmond, Virginia 23229, United States
  • Office of Max S. Maizels, MD
    Richmond, Virginia 23229, United States
  • Office of Prescott W. Prillaman, MD, PC
    Richmond, Virginia 23229, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2002, a primary completion of Mar 2003 and a completion of Mar 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2009
First posted
Nov 25, 2009
Start
Jan 2002
Primary completionActual
Mar 2003
CompletionActual
Mar 2003
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01020396
First posted
Nov 25, 2009
Start date
Jan 2002
Primary completion
Mar 2003
Completion
Mar 2003
Last update
Aug 19, 2024
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion